Indices
Endpoint Index
A simple equal-weight index of active Endpoint Arena markets. It updates with live YES prices, so you can quickly see whether the market is getting more or less confident about upcoming trial readouts.
Index Tape
Index Level
51.3%
0%50%100%
Active Markets
6
Move From Open
-1.7 pts
Range
39%-63%
Index History
Latest
51.3%
Since Start
-6.7 pts
Markets
6
Market Mix
Clinical Sleeves
Trend
Avg YES
Move
Weight
Oncology3 markets
Trend
Avg YES46.1%
Move+1.1 pts
Weight50.0%
CNS1 market
Trend
Avg YES71.2%
Move+10.2 pts
Weight16.7%
Infectious Disease1 market
Trend
Avg YES70.4%
Move+2.4 pts
Weight16.7%
Other1 market
Trend
Avg YES28.1%
Move-25.9 pts
Weight16.7%
Phase Sleeves
Trend
Avg YES
Move
Weight
Phase 36 markets
Trend
Avg YES51.3%
Move-1.7 pts
Weight100.0%
Constituents
Trial
Ticker
Drug Market
Readout
Sleeve
Phase
YES
Move
Weight
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Ticker
PFE
Drug Market
—
Readout
12/30/26
Sleeve
Oncology
Phase
Phase 3
YES
34.5%
Move
-4.5
Weight
16.7%
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
PFE
—
est. opp.
12/30/26
Oncology
Phase 3
34.5%
-4.5
16.7%
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Ticker
INCY
Drug Market
—
Readout
12/31/26
Sleeve
Other
Phase
Phase 3
YES
28.1%
Move
-25.9
Weight
16.7%
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
INCY
—
est. opp.
12/31/26
Other
Phase 3
28.1%
-25.9
16.7%
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Ticker
AURA
Drug Market
—
Readout
11/15/27
Sleeve
Oncology
Phase
Phase 3
YES
58.0%
Move
+8.0
Weight
16.7%
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
AURA
—
est. opp.
11/15/27
Oncology
Phase 3
58.0%
+8.0
16.7%
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Ticker
SNY
Drug Market
—
Readout
12/31/27
Sleeve
CNS
Phase
Phase 3
YES
71.2%
Move
+10.2
Weight
16.7%
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
SNY
—
est. opp.
12/31/27
CNS
Phase 3
71.2%
+10.2
16.7%
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ticker
AMGN
Drug Market
—
Readout
02/29/28
Sleeve
Oncology
Phase
Phase 3
YES
45.8%
Move
-0.2
Weight
16.7%
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
AMGN
—
est. opp.
02/29/28
Oncology
Phase 3
45.8%
-0.2
16.7%
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
Ticker
MRK
Drug Market
—
Readout
09/30/28
Sleeve
Infectious Disease
Phase
Phase 3
YES
70.4%
Move
+2.4
Weight
16.7%
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
MRK
—
est. opp.
09/30/28
Infectious Disease
Phase 3
70.4%
+2.4
16.7%